Dr. Brett Zirkle is a law clerk in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he has been a member of the firm's patents and innovations practice since 2019. Brett has experience in patent prosecution, portfolio management, and diligence (buy and sell side) across discovery and preclinical stage biologics, clinical stage therapeutics, and omics-based biotechnologies.
Brett received his J.D. from the University of San Diego and his Ph.D. in Genetic, Molecular, and Cellular Biology from University of Southern California's Keck School of Medicine where his doctoral research focused on the structural biology, biochemistry, and genomics of immune response proteins, including antibodies and DNA editing enzymes. Prior to attending USC, Brett was a NIH Intramural Research Award Fellow within the National Institute of Allergy and Infectious Diseases, Vaccine Research Center in which his research focused on HIV antibody structural biology and biochemistry. He was also the recipient of NASA West Virginia Space Grant for research related to field of molecular biology.
Brett is admitted to practice before USPTO. He is not yet admitted in California and therefore not authorized to practice law in California.
Dr. Brett Zirkle is a law clerk in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he has been a member of the firm's patents and innovations practice since 2019. Brett has experience in patent prosecution, portfolio management, and diligence (buy and sell side) across discovery and preclinical stage biologics, clinical stage therapeutics, and omics-based biotechnologies.
Brett received his J.D. from the University of San Diego and his Ph.D. in Genetic, Molecular, and Cellular Biology from University of Southern California's Keck School of Medicine where his doctoral research focused on the structural biology, biochemistry, and genomics of immune response proteins, including antibodies and DNA editing enzymes. Prior to attending USC, Brett was a NIH Intramural Research Award Fellow within the National Institute of Allergy and Infectious Diseases, Vaccine Research Center in which his research focused on HIV antibody structural biology and biochemistry. He was also the recipient of NASA West Virginia Space Grant for research related to field of molecular biology.
Brett is admitted to practice before USPTO. He is not yet admitted in California and therefore not authorized to practice law in California.
- J.D., University of San Diego School of Law, 2023
- Ph.D., Genetic, Molecular, and Cellular Biology, Keck School of Medicine of USC, 2019
- B.S., Shepherd University, 2005
- U.S. Patent and Trademark Office
- Not admitted in California
- J.D., University of San Diego School of Law, 2023
- Ph.D., Genetic, Molecular, and Cellular Biology, Keck School of Medicine of USC, 2019
- B.S., Shepherd University, 2005
- U.S. Patent and Trademark Office
- Not admitted in California
Select Publications
- Co-author with X. Xiao, H. Yang, V. Arutiunian, Y. Fang, G. Besse, C. Morimoto, X.S. Chen, "Structural Determinants of APOBEC3B Non-Catalytic Domain for Molecular Assembly and Catalytic Regulation," 45(12) Nucleic Acids Res. 7494-7506, 2017
- Co-author with F. Ito, H. Yang, X. Xiao, S.X. Li, A. Wolfe, V. Arutiunian, X.S. Chen, "Understanding the Structure, Multimerization, Subcellular Localization and mC Selectivity of a Genomic Mutator and Anti-HIV Factor APOBEC3H," 8(1) Sci Rep. 3763, 2018
- Co-author with W. Wang, J. Nie, J. Ma, K. Gao, X.S. Chen, W. Huang, W. Kong, Y. Wang, "N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03," 69(3) J Acquir Immune Defic. Syndr. 270-7, 2015
- Co-author with G. Ofek, Y. Yang, Z. Zhu, K. McKee, B. Zhang, G.Y. Chuang, I.S. Georgiev, S. O'Dell, N. Doria-Rose, J.R. Mascola, D.S. Dimitrov, P.D. Kwong, "Structural Basis for HIV-1 Neutralization by 2F5-like Antibodies m66 and m66.6.," 88(5) J Virol. 2426-41, 2014
- Co-author with C.Z. Plautz, M.J. Deshotel, R.M. Grainger, "Early Stages of Induction of Anterior Head Ectodermal Properties in Xenopus Embryos are Mediated by Transcriptional Cofactor ldb1," 243(12) Dev Dyn. 1606-18, 2014
Select Publications
- Co-author with X. Xiao, H. Yang, V. Arutiunian, Y. Fang, G. Besse, C. Morimoto, X.S. Chen, "Structural Determinants of APOBEC3B Non-Catalytic Domain for Molecular Assembly and Catalytic Regulation," 45(12) Nucleic Acids Res. 7494-7506, 2017
- Co-author with F. Ito, H. Yang, X. Xiao, S.X. Li, A. Wolfe, V. Arutiunian, X.S. Chen, "Understanding the Structure, Multimerization, Subcellular Localization and mC Selectivity of a Genomic Mutator and Anti-HIV Factor APOBEC3H," 8(1) Sci Rep. 3763, 2018
- Co-author with W. Wang, J. Nie, J. Ma, K. Gao, X.S. Chen, W. Huang, W. Kong, Y. Wang, "N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03," 69(3) J Acquir Immune Defic. Syndr. 270-7, 2015
- Co-author with G. Ofek, Y. Yang, Z. Zhu, K. McKee, B. Zhang, G.Y. Chuang, I.S. Georgiev, S. O'Dell, N. Doria-Rose, J.R. Mascola, D.S. Dimitrov, P.D. Kwong, "Structural Basis for HIV-1 Neutralization by 2F5-like Antibodies m66 and m66.6.," 88(5) J Virol. 2426-41, 2014
- Co-author with C.Z. Plautz, M.J. Deshotel, R.M. Grainger, "Early Stages of Induction of Anterior Head Ectodermal Properties in Xenopus Embryos are Mediated by Transcriptional Cofactor ldb1," 243(12) Dev Dyn. 1606-18, 2014
ONL Therapeutics is the first and only clinical-stage company focused on the unique mechanism of action (MOA) preventing Fas-mediated death of retinal cells and inflammatory signaling pathways, the root causes of vision loss and blindness. The proceeds from the Series D financing will advance the development of ONL1204 Ophthalmic Solution with the initiation of a Phase 2 global study for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).
The Wilson Sonsini team that advised ONL Therapeutics on patent matters related to the financing included Greg Mitchell, Brett Zirkle, Tess Oram, and Lou Lieto.
For more information, please see ONL Therapeutics’ news release.
- Privacy Policy
- Terms of Use
- Accessibility